Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.
about
Cannabinoids as therapeutic agents in cancer: current status and future implicationsValidation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targetsTargeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigmTranscriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumorsAntitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancerExpression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic targetNeuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.Personalized therapies in the cancer "omics" eraBiological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.DNA-damage related genes and clinical outcome in hormone receptor positive breast cancerTranscriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer.Transcriptome evolution from breast epithelial cells to basal-like tumors.
P2860
Q26866298-846E2237-69AD-48A9-927F-2D8B4D97D790Q31103913-06B4436B-B82F-4BE9-9829-B8B61D7F6393Q33591876-780AB053-58D0-411D-8C75-7DA09FE8D7AEQ33994282-34C5D5D7-7A2E-46F8-A821-C45AC828B75CQ36363060-D6A76638-5C93-4102-A0DE-93FB1BEB91CBQ36413944-C49CE4FF-C358-4F17-BC56-DAEA3546A3FBQ37182453-DF125F56-469F-426C-A71B-2977B43E9CE1Q37564335-87E9489E-166C-4FF9-A498-D1DFD2B42667Q37776547-ABC2F361-4798-4F5D-88E3-C8DCE94FCDCDQ38171330-7397A1A3-C53A-4E73-971D-5BA4F3D3FDBAQ38773872-1B6AF810-A634-44D3-AC2B-F7364598F411Q38846435-BE1A6C86-6A6A-4043-BD8A-36EC3AB3E82AQ39660788-78D6D400-9244-43E9-BA4D-A99B4F6D2E48Q39816322-920FD842-3B20-4A2C-B3AE-83776821FAA2Q42362638-A62DFB8C-CC77-4887-A8A8-DB6B00592DCBQ42489330-B9104D0E-C0AD-4227-8267-1D19A7FD05B3Q50128372-3FB45BBB-6F7B-4082-9F13-232FDE0E930D
P2860
Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identifying breast cancer drug ...... d and future targeted options.
@en
Identifying breast cancer drug ...... d and future targeted options.
@nl
type
label
Identifying breast cancer drug ...... d and future targeted options.
@en
Identifying breast cancer drug ...... d and future targeted options.
@nl
prefLabel
Identifying breast cancer drug ...... d and future targeted options.
@en
Identifying breast cancer drug ...... d and future targeted options.
@nl
P1476
Identifying breast cancer drug ...... ed and future targeted options
@en
P2093
Atanasio Pandiella
P304
P356
10.1158/1078-0432.CCR-07-1630
P407
P577
2008-02-01T00:00:00Z